This company listing is no longer active
Acerus Pharmaceuticals Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Wichtige Informationen
-22.8%
Wachstumsrate der Gewinne
23.7%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 23.1% |
Wachstumsrate der Einnahmen | -32.5% |
Eigenkapitalrendite | n/a |
Netto-Marge | -924.3% |
Letzte Ertragsaktualisierung | 30 Sep 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30Aufschlüsselung der Einnahmen und Ausgaben
Wie Acerus Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Sep 22 | 3 | -28 | 20 | 7 |
30 Jun 22 | 3 | -29 | 20 | 7 |
31 Mar 22 | 3 | -28 | 22 | 5 |
31 Dec 21 | 2 | -34 | 22 | 5 |
30 Sep 21 | 2 | -32 | 20 | 4 |
30 Jun 21 | 2 | -34 | 21 | 3 |
31 Mar 21 | 1 | -33 | 20 | 3 |
31 Dec 20 | 1 | -24 | 18 | 3 |
30 Sep 20 | 1 | -21 | 17 | 2 |
30 Jun 20 | 1 | -19 | 14 | 2 |
31 Mar 20 | 2 | -16 | 12 | 2 |
31 Dec 19 | 4 | -16 | 10 | 3 |
30 Sep 19 | 5 | -17 | 9 | 3 |
30 Jun 19 | 7 | -16 | 8 | 3 |
31 Mar 19 | 8 | -19 | 9 | 3 |
31 Dec 18 | 7 | -19 | 9 | 2 |
30 Sep 18 | 8 | -16 | 8 | 3 |
30 Jun 18 | 7 | -16 | 8 | 2 |
31 Mar 18 | 7 | -11 | 7 | 2 |
31 Dec 17 | 7 | -9 | 7 | 2 |
30 Sep 17 | 6 | -7 | 6 | 2 |
30 Jun 17 | 6 | -5 | 6 | 2 |
31 Mar 17 | 15 | 3 | 6 | 2 |
31 Dec 16 | 24 | 11 | 5 | 2 |
30 Sep 16 | 31 | 3 | 5 | 2 |
30 Jun 16 | 32 | 5 | 5 | 2 |
31 Mar 16 | 24 | -3 | 5 | 3 |
Qualität der Erträge: ASP is currently unprofitable.
Wachsende Gewinnspanne: ASP is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: ASP is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Beschleunigtes Wachstum: Unable to compare ASP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: ASP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: ASP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.